IGF-1 LR3: Insulin-Like Growth Factor Research in the Laboratory

Background

Insulin-like growth factor 1 (IGF-1) is a 70-amino-acid peptide hormone structurally related to insulin and produced predominantly in the liver under growth hormone (GH) stimulation. It mediates most of GH's anabolic effects — promoting cell proliferation, protein synthesis, and differentiation in skeletal muscle, cartilage, bone, and many other tissues.

In circulation, over 98% of native IGF-1 is bound to IGF binding proteins (IGFBPs, primarily IGFBP-3 with the acid-labile subunit), which sharply limits free bioactive IGF-1 available to tissues. This binding complicates both native IGF-1 pharmacokinetics and its use as a consistent experimental tool. IGF-1 LR3 (Long R3 IGF-1) was engineered specifically to address this limitation for laboratory research.

Molecular design of LR3

IGF-1 LR3 is a recombinant 83-amino-acid analog with two modifications from native IGF-1:

• 13-amino-acid N-terminal extension (MFPAMPLSSLFVN) — increases molecular weight and masks IGFBP-binding residues
• Arginine-3 substitution — replaces glutamate at position 3 with arginine, dramatically reducing affinity for IGFBPs

The result: ~3× longer functional half-life in serum-containing cell culture and substantially higher free/bioactive fraction compared with native IGF-1 at equivalent molar concentrations. Molecular weight: ~9,200 Da.

Receptor pharmacology

IGF-1 LR3 retains full affinity for the IGF-1 receptor (IGF-1R) — a receptor tyrosine kinase that autophosphorylates on ligand binding and activates two major downstream cascades:

• PI3K → AKT → mTOR — drives protein synthesis, cell survival, and anabolic signaling; central to muscle hypertrophy research
• Ras → Raf → MEK → ERK — drives proliferation and differentiation programs

At supraphysiological concentrations IGF-1 LR3 can cross-activate the insulin receptor; researchers typically use concentration ranges that avoid this confound.

What laboratories typically study

• Cell proliferation and differentiation — C2C12 myoblast-to-myotube transitions, primary myoblast cultures, bone marrow stromal cells
• Protein synthesis — SUnSET or puromycin incorporation assays, polysome profiling, AKT/mTOR phosphorylation status
• Muscle biology — fiber-type shifts, atrophy/hypertrophy markers, satellite cell activation in explant models
• Chondrocyte and cartilage research — matrix production, articular cartilage repair models
• Cancer biology — IGF-1R signaling is a well-studied oncology target; LR3 serves as a consistent agonist reference
• Neural research — IGF-1 signaling in neuronal survival, neuroprotection models, and synaptic plasticity studies

Handling and quality

• Supplied as lyophilized powder; typical research format 1 mg
• Store lyophilized at -20°C, protected from light and moisture
• Reconstitute in dilute acetic acid (0.01 M) or manufacturer-specified buffer, then dilute into assay medium
• Reconstituted solution stable ~4 weeks at 2–8°C in sealed vial
• Purity verified by HPLC (≥95–99% typical for recombinant material) with SDS-PAGE and mass-spectrometric identity; obtain batch COA

Related reading

• /research/igf-1-lr3 — compound profile with molecular data
• /category/muscle-growth-research — broader category
• /blog/cjc-1295-ipamorelin-mechanism — upstream GH/IGF axis modulators
• /guides/how-to-reconstitute-peptides — solvent selection for recombinant proteins

RUO disclaimer

For laboratory research use only. Not intended to diagnose, treat, cure, or prevent any disease. Not for human consumption outside approved research settings.